{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:26:21Z","timestamp":1785338781632,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are blistering disorders mediated predominantly by IgG1 and IgG4 antibodies directed towards desmoglein (Dsg)1 and\/or 3. The anti-CD20 monoclonal antibody rituximab is a highly effective treatment for PV, although less is known regarding its efficacy in the treatment of PF and the dynamics of anti-Dsg1 IgG subclasses post rituximab treatment. We therefore investigated clinical outcomes and anti-Dsg antibody dynamics in 105 pemphigus patients (89 with PV, 16 with PF) treated with rituximab. Similar treatment responses were observed in PV and PF, although there were significant differences in anti-Dsg antibody dynamics post treatment, with a greater reduction of anti-Dsg1 in anti-Dsg1 positive PV than in PF which corresponded to a reduction in predominantly IgG4 subclass antibodies. Baseline clinical parameters that correlated with complete remission were increased age and lower disease duration. We identified lower circulating B cell counts in older patients and enrichment in anti-Dsg1 IgG4 and anti-Dsg3 IgA with longer disease duration, suggesting that immune senescence and increased clonal diversity could account for more and less favourable treatment responses respectively. Reductions in anti-Dsg1 post rituximab had greater prognostic value than anti-Dsg3 and this applied to both IgG1 and IgG4 subclasses. The study findings therefore suggest disparate disease biology underlying anti-Dsg1 and 3 responses and advances our knowledge of the biology underlying shorter disease duration and increased age as positive predictors of treatment response to rituximab.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1713987","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:41Z","timestamp":1765521161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab"],"prefix":"10.3389","volume":"16","author":[{"given":"Vishvan","family":"Naidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita A.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yalcinkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yathavi","family":"Charavanamuttu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruva","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadira","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Mee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitesh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Semkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia N.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Setterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Tull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0232","article-title":"Immunobullous disease","volume":"21","author":"Tull","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16561","article-title":"Long-term outcomes of rituximab therapy in pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884931","article-title":"Rituximab - progress but still not a final resolution for pemphigus patients: clinical report from a single center study","volume":"13","author":"Mise","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal outcomes after rituximab therapy for pemphigus vulgaris","volume":"142","author":"Tovanabutra","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: A post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.6654","article-title":"Long-term efficacy and safety of rituximab in patients with pemphigus foliaceus compared with pemphigus vulgaris","volume":"161","author":"Tedbirt","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849790","article-title":"The diversity of serum anti-DSG3 igG subclasses has a major impact on pemphigus activity and is predictive of relapses after treatment with rituximab","volume":"13","author":"Golinski","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27393","article-title":"Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >\/=65 years old","volume":"64","author":"Doughty","year":"2021","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00782-x","article-title":"Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register","volume":"37","author":"Mielnik","year":"2020","journal-title":"Drugs Aging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12630","article-title":"Prognostic factors in pemphigus vulgaris and pemphigus foliaceus","volume":"170","author":"Saha","year":"2014","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"adv27140","DOI":"10.2340\/actadv.v105.27140","article-title":"Prognostic factors predicting remission following rituximab therapy for pemphigus vulgaris","volume":"105","author":"Raviv","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J\u00a0Dermatol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198906013202206","article-title":"The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)","volume":"320","author":"Rock","year":"1989","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1713987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:43Z","timestamp":1765521163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1713987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1713987"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1713987","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1713987"}}